For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 2,361 | |||
| General and administrative | 2,687 | |||
| Total operating expense | 5,048 | |||
| Loss from operations | -5,048 | |||
| Interest expense-Nonrelated Party | 31 | |||
| Interest expense-Related Party | 10 | |||
| Change in fair value of other liabilities and derivatives-Nonrelated Party | 93 | |||
| Change in fair value of other liabilities and derivatives-Related Party | 7 | |||
| Other income (expense), net | 18 | |||
| Total other income (expenses), net | -123 | |||
| Loss before income taxes | -5,171 | |||
| Income tax provision | 10 | |||
| Net loss | -5,181 | |||
| Net loss attributable to noncontrolling interest | -32 | |||
| Net loss attributable to controlling interest | -5,149 | |||
| Deemed dividend on warrants | -5,673 | |||
| Net loss attributable to common stockholders | -10,822 | |||
| Basic EPS | -2.21 | |||
| Diluted EPS | -2.21 | |||
| Basic Average Shares | 4,907 | |||
| Diluted Average Shares | 4,907 | |||
Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc. (CLDI)